Module Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 12 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 51.15%
- Profit Growth 890.41%
- Ebitda 8605.15%
- Net Worth 484.32%
- Total Assets 13.21%
About Module Pharmaceutical
Module Pharmaceutical Private Limited (MPPL) is a Private Limited Indian Non-Government Company incorporated in India on 24 February 2012 and has a history of 12 years and 11 months. Its registered office is in Bangaluru, Karnataka, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Shahabuddin Khan and Iram Ismail serve as directors at the Company.
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24100KA2012PTC062712
- Company No.
062712
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Feb 2012
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Who are the key members and board of directors at Module Pharmaceutical?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shahabuddin Khan  | Managing Director | 24-Feb-2012 | Current |
Board Members (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Iram Ismail | Director | 21-Nov-2016 | Current |
Financial Performance of Module Pharmaceutical.
Module Pharmaceutical Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 51.15% increase. The company also saw a substantial improvement in profitability, with a 890.41% increase in profit. The company's net worth Soared by an impressive increase of 484.32%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Module Pharmaceutical?
In 2022, Module Pharmaceutical had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Module Pharmaceutical?
Unlock and access historical data on people associated with Module Pharmaceutical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Module Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Module Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
